Inoue-Yamauchi et al., 2017 - Google Patents
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapyInoue-Yamauchi et al., 2017
View HTML- Document ID
- 9157624232936075718
- Author
- Inoue-Yamauchi A
- Jeng P
- Kim K
- Chen H
- Han S
- Ganesan Y
- Ishizawa K
- Jebiwott S
- Dong Y
- Pietanza M
- Hellmann M
- Kris M
- Hsieh J
- Cheng E
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anti- cancer targets. Using small cell lung cancer (SCLC) as a model, we demonstrated the presence of differential addiction of cancer cells to anti-apoptotic BCL-2, BCL-XL or MCL-1 …
- 201000011510 cancer 0 title abstract description 40
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Inoue-Yamauchi et al. | Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy | |
| Bertran-Alamillo et al. | AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy | |
| He et al. | Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells | |
| Tanaka et al. | Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM-and PUMA-mediated apoptosis | |
| Dey et al. | Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition | |
| Zhao et al. | Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer | |
| Nguyen et al. | Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma | |
| Kong et al. | WEE1 inhibitor: clinical development | |
| Jo et al. | SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors | |
| Trigg et al. | The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status | |
| Jinawath et al. | Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma | |
| Li et al. | Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer | |
| Yuan et al. | BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and-resistant ovarian cancer cells | |
| Smida et al. | MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated | |
| Nair et al. | Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer | |
| Dang et al. | Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer | |
| Ye et al. | Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia | |
| Ou et al. | A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer | |
| Sun et al. | The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA | |
| Ku et al. | Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer | |
| Zhang et al. | SPOP mutation induces DNA methylation via stabilizing GLP/G9a | |
| Xie et al. | RETRACTED ARTICLE: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine | |
| Wang et al. | Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | |
| Kolb et al. | ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation | |
| Pinton et al. | PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1 |